Skip to content
OpenCapital
Get started

Biogen BIIB Reportable Segment — Research and development:

Similar metrics at other companies

Lexicon Pharmaceuticals logo
LXRXReportable Segment — R&D
$11.39M-16.3%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — R&D
$16M-27.3%
Vaxcyte, Inc. logo
PCVXReportable Segment — R&D
$256.43M+147%
Aquestive Therapeutics, Inc. logo
AQSTReportable Segment — R&D
$4.2M-21.6%
Tarsus Pharmaceuticals, Inc. logo
TARSReportable Segment — R&D
$22.35M+55.1%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — R&D
$57.09M+21.8%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M—
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%—
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's reportable segment — research and development:.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's reportable segment — research and development:?
Biogen (BIIB) reported reportable segment — research and development: of $172.8M in Q1 2026.
How has Biogen's reportable segment — research and development: changed year-over-year?
Biogen's reportable segment — research and development: decreased by 3.2% year-over-year, from $178.5M to $172.8M.
What is the long-term trend for Biogen's reportable segment — research and development:?
Over 3 years (2022 to 2025), Biogen's reportable segment — research and development: has grown at a -1.7% compound annual growth rate (CAGR), from $729.6M to $692.9M.
What does reportable segment — research and development: mean?
This metric tracks the capital and operational expenditures dedicated to discovering and developing new pharmaceutical compounds and clinical trials within the segment. It reflects the company's commitment to long-term innovation and the replenishment of its drug pipeline. High investment levels are essential for sustaining future growth in the biotech industry.